Lupin's US subsidiary has received final US FDA approval for its ANDA for lamotrigine 25mg, 100mg, 150mg and 200mg tablets, which are generic versions of GlaxoSmithKline's anticonvulsant, Lamictal tablets. Lupin's potential launch of its product comes well after Teva Pharmaceutical Industries introduced the first generic version of Lamictal tablets in 2008, following a settlement of patent litigation with GSK in February 2005. Under the settlement, GlaxoSmithKline granted Teva the exclusive right to manufacture and sell a generic version of Lamictal during the six-month paediatric exclusivity period, which ended on 22 January 2009. Lamictal tablets had sales of about $452 million for the 12 months ended March 2010, according to IMS Health. Teva launched lamotrigine chewable tablets (5mg and 25mg) in 2005, and the Indian company, Aurobindo Pharma, received final FDA approval for lamotrigine 5mg and 25mg chewable, dispersible tablets last November.
Lupin gets US FDA nod for lamotrigine tablets
Lupin's US subsidiary has received final US FDA approval for its ANDA for lamotrigine 25mg, 100mg, 150mg and 200mg tablets, which are generic versions of GlaxoSmithKline's anticonvulsant, Lamictal tablets. Lupin's potential launch of its product comes well after Teva Pharmaceutical Industries introduced the first generic version of Lamictal tablets in 2008, following a settlement of patent litigation with GSK in February 2005. Under the settlement, GlaxoSmithKline granted Teva the exclusive right to manufacture and sell a generic version of Lamictal during the six-month paediatric exclusivity period, which ended on 22 January 2009. Lamictal tablets had sales of about $452 million for the 12 months ended March 2010, according to IMS Health. Teva launched lamotrigine chewable tablets (5mg and 25mg) in 2005, and the Indian company, Aurobindo Pharma, received final FDA approval for lamotrigine 5mg and 25mg chewable, dispersible tablets last November.
More from New Products
UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.
The US FDA approved taletrectinib for the treatment of ROS1+ NSCLC, where Nuvation hopes it will lead the category with a best-in-class position.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.
More from Scrip
After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.
Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.
Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.